Clinical trial
Rapid Infusion of Immune Globulin Intravenous (Human) In Primary…
NCT00220766 · Grifols Therapeutics LLC, Industry · Completed
Key facts
| NCT number | NCT00220766 |
|---|---|
| Title | Rapid Infusion of Immune Globulin Intravenous (Human) In Primary Immunodeficiency Patients |
| Official title | IGIV-C 10% Rapid Infusion Trial in Primary Immune Deficient Patients |
| Lead sponsor | Grifols Therapeutics LLC, Industry |
| Status | Completed |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Immunologic Deficiency Syndrome, Agammaglobulinemia, Severe Combined Immunodeficiency, Wiskott-Aldrich Syndrome, Common Variable Immunodeficiency |
| Intervention type | Drug |
| Interventions | Immune Globulin Intravenous [Human], 10% Caprylate/Chromatography Purified, Dextrose, 5% in Water |
| Enrollment | 100 |
| Start date | Aug 1, 2002 |
| Primary completion | Aug 1, 2002 |
| Completion | Mar 1, 2004 |
| First posted | Sep 22, 2005 |
| Last update posted | Sep 25, 2009 |
| Countries | Canada, United States |
At a glance
- 10–99 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: